Table 3.

Relative vaccine effectiveness of three doses versus two doses of BNT162b2 and CoronaVac against COVID-19

	BNT162b2	CoronaVac
Mild or moderate disease
20–59 years	59·8% (49·7–68·1)	35·7% (22·1–47·3)
≥60 years	71·6% (55·6–82·8)	46·9% (29·6–60·6)
Severe or fatal disease
20–59 years	60·1% (24·2–81·0)	85·2% (67·2–94·4)
60–69 years	84·5% (62·8–94·8)	85·6% (72·7–93·1)
70–79 years	88·3% (69·5–96·6)	76·9% (63·9–86·0)
≥80 years	64·9% (29·3–84·4)	87·9% (79·5–93·3)
Mortality
20–59 years	71·2% (25·5–91·6)	91·0% (61·0–97·9)
60–69 years	84·2% (54·1–96·3)	92·5% (79·3–98·2)
70–79 years	90·0% (66·5–98·4)	82·6% (68·6–91·5)
≥80 years	61·8% (16·4–84·9)	88·6% (79·1–94·4)

Data are effectiveness (95% CI).